Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary) ; Nivolumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2019 Trial design presented at the 110th Annual Meeting of the American Association for Cancer Research
- 16 Apr 2018 Status changed from not yet recruiting to recruiting.